Form 4: OptimizeRx Executive Receives Stock Options and Restricted Stock Units

OptimizeRx's General Counsel and CCO, Marion Odence-Ford, was granted stock options and restricted stock units on December 23, 2024.

Summary

• Marion Odence-Ford, General Counsel and CCO of OptimizeRx Corp, received 41,408 restricted stock units and 77,742 stock options on December 23, 2024.
• The restricted stock units represent a contingent right to receive shares of OptimizeRx common stock and will vest in three equal annual installments starting December 23, 2025.
• The stock options also vest in three equal annual installments beginning December 23, 2025, and expire on December 23, 2027.
• The exercise price for the stock options is $4.83.
• Following these transactions, Ms. Odence-Ford beneficially owns 68,638 shares of common stock and 77,742 stock options.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There are no negative implications.

Positives

• The grant of stock options and restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.
• The grants are a form of compensation that does not require immediate cash outlay from the company.

Risks

• The value of the stock options and restricted stock units is dependent on the future performance of OptimizeRx's stock price.
• If the stock price declines, the value of these grants will decrease.

Future Outlook

The vesting of the stock options and restricted stock units is contingent on the executive's continued employment and the company's performance.

Industry Context

This type of equity compensation is common practice for publicly traded companies to incentivize and retain key executives.

Comparison to Industry Standards

• Equity grants are a standard component of executive compensation packages in the technology and healthcare sectors, similar to companies like Veeva Systems and Teladoc Health.
• The vesting schedule of three years is also typical, aligning with industry norms for long-term incentive plans.
• The specific number of shares and option grants would be benchmarked against companies of similar size and market capitalization.

Stakeholder Impact

• Shareholders may view this as a positive sign of aligning management interests with company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, equity compensation, insider trading, executive compensation, OptimizeRx, OPRX